Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

argenx and Monash University partner against autoimmune diseases

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...

Archer completes potassium sensing alpha prototype

Quantum technology company Archer Materials Limited has developed an early Biochip prototype...

Farm animals and aquaculture cryopreservation partnership announced

Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...

Content from other channels on our network

A matter of influence: getting over the 'ick' with recycled water

How sustainability is shaping network strategy

Upcycled mattresses to become sustainable insulation

Study finds the most effective global climate policies

UV used to make recyclable, sustainable polymers

Endress+Hauser acquires particle analysis specialist

ABB introduces DCS modernisation program

foodpro 2026 now open for registrations

The missing middle: Solving the logic solver gap in SIS design

Queensland Government opens $79m manufacturing grant program

St Vincent's Hospital Sydney junior doctors class action underway

Hospital waiting times remain high, new Productivity Commission data reveals

From vision to vigilance: building a secure digital future for health care

The Emergency Department Access & Performance Conference

REDFEB highlights the impacts of chronic stress on the heart